XinThera
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
XinThera was a San Diego-based biotechnology company founded in 2021 by Stephen Kaldor, Qing Dong, and Gene Hung. It used structure-based drug design and computational chemistry to develop best-in-class small-molecule precision medicines for cancer and immunologic diseases, including selective PARP1 inhibitors. Backed by Foresite Capital, OrbiMed, and TTM Capital, it was acquired by Gilead Sciences in May 2023.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Founded in San Diego by Stephen Kaldor, Qing Dong, and Gene Hung; raised a $30 million Series A in May 2021.
- Series B
Closed a Series B round in August 2021 to advance its oncology and immunology pipeline.
- Acquired by Gilead
Gilead Sciences agreed to acquire XinThera to strengthen its early oncology and inflammation pipeline; financial terms were not disclosed (PitchBook recorded the deal at $200 million).
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.